6.6.2 Bisphosphonates and other drugs affecting bone metabolism
Alendronic acid
Alendronic acid 70mg effervescent tablets sugar free
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
Alendronic acid 70mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
Denosumab
Denosumab 120mg/1.7ml solution for injection vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Malignant disease and immunosuppression | Bone issues associated with malignancy |
Denosumab 60mg/1ml solution for injection pre-filled syringes
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
Ibandronic acid
Ibandronic acid 150mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
Ibandronic acid 50mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Malignant disease and immunosuppression | Bone issues associated with malignancy |
Pamidronate disodium
Pamidronate disodium 15mg/5ml solution for infusion vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
| Malignant disease and immunosuppression | Bone issues associated with malignancy |
Pamidronate disodium 30mg/10ml solution for infusion vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
| Malignant disease and immunosuppression | Bone issues associated with malignancy |
Pamidronate disodium 90mg/10ml solution for infusion vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
| Malignant disease and immunosuppression | Bone issues associated with malignancy |
Risedronate sodium
Risedronate sodium 30mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Paget’s disease |
Risedronate sodium 35mg tablets
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
Romosozumab
Evenity 105mg/1.17ml solution for injection pre-filled pens
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
Zoledronic acid
Zoledronic acid 4mg/100ml infusion bags
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
| Malignant disease and immunosuppression | Bone issues associated with malignancy |
Zoledronic acid 4mg/100ml solution for infusion vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Malignant disease and immunosuppression | Bone issues associated with malignancy |
Zoledronic acid 4mg/5ml solution for infusion vials
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
| Malignant disease and immunosuppression | Bone issues associated with malignancy |
Zoledronic acid 5mg/100ml infusion bags
On formulary for the treatment of:
| Therapeutic Area | Condition |
|---|---|
| Endocrine system | Osteoporosis |
| Endocrine system | Paget’s disease |